Vascular access devices for prolonged intravenous therapy regimens in people diagnosed with cancer

Caitriona Duggan; Peter J Carr; Nicole Gavin; Stewart Walsh; Andrew Simpkin; Joshua Byrnes; Christina H Ruhlmann; Raymond J Chan; Orlaith Hernon

doi:10.1002/14651858.CD015667

Vascular access devices for prolonged intravenous therapy regimens in people diagnosed with cancer

Cochrane Database Syst Rev. 2024 Aug 30;8(8):CD015667. doi: 10.1002/14651858.CD015667.

Authors

Caitriona Duggan^{1

2}, Peter J Carr¹, Nicole Gavin³, Stewart Walsh⁴, Andrew Simpkin⁵, Joshua Byrnes⁶, Christina H Ruhlmann^{7

8}, Raymond J Chan⁹, Orlaith Hernon¹

Affiliations

¹ School of Nursing and Midwifery, University of Galway, Galway, Ireland.
² Oncology Department, Portiuncula University Hospital, Galway, Ireland.
³ Royal Brisbane and Women's Hospital, NHMRC Centre of Research Excellence in Nursing, Centre for Health Practice Innovation, Menzies Health Institute Queensland, Griffith University, Brisbane, Australia.
⁴ Discipline of Surgery, Lambe Institute, Galway, Ireland.
⁵ School of Mathematics, Statistics and Applied Mathematics, University of Galway, Galway , Ireland.
⁶ Centre for Applied Health economics, Griffith University, Queensland, Australia.
⁷ Department of Oncology, Odense University Hospital, Odense, Denmark.
⁸ Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
⁹ School of Nursing, Queensland University of Technology, Brisbane, Australia.

Abstract

This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the relative effectiveness and vascular access device (VAD)-related complications of VADs in people requiring prolonged systemic anti-cancer treatment.

Publication types

Systematic Review

MeSH terms

Antineoplastic Agents* / administration & dosage
Antineoplastic Agents* / adverse effects
Humans
Infusions, Intravenous / instrumentation
Neoplasms* / drug therapy
Randomized Controlled Trials as Topic
Vascular Access Devices* / adverse effects

Substances

Antineoplastic Agents